Two KWF grants for LUMC on AI for precision oncology
This week, the Dutch Cancer Foundation (KWF) has awarded two research grants to LUMC researchers that include the development of advanced AI technology to improve and personalize oncological treatment.
One project headed by dr. Tjalling Bosse, department of Pathology, has an AI component on developing and using AI technology for automatic biomarker detection and quantification (RAD51 accumulation) in a large series of tumor tissue samples. This signal can potentially predict chemotherapy therapy response for individual ovarian cancer, endometrial cancer and breast cancer patients, and may help identify patients that have become resistant against specific types of chemotherapy.
The second project led by dr. Mark Burgmans, department of Radiology, develops AI technologies to improve liver tumour ablation procedures by accurately evaluating the ablation results during the procedure. AI techniques will be developed for accurate localization and segmentation of the tumour regions and ablation zones to evaluate the extent of the ablation margins to avoid the recurrence of tumours.
In both projects, dr. Jouke Dijkstra from the Lab Clinical and Experimental Image Processing (LKEB, Department of Radiology) leads the research on the AI technology development required to process the medical and pathological images. The LKEB has ample experience with developing novel AI technologies for medical imaging based on deep learning. These two newly granted projects are an important step to further strengthen the use of AI for precision oncology, and is embedded in the Leiden University AI research program SAILS.